Abstract:Abstract Abstract 1215 Sirt1 is a NAD+-dependent class III histone deacetylase that regulates various cellular processes including cell growth, apoptosis, senescence and stress responses. Variations in Sirt1 expression and activity are associated with pleiotropic and profound biological effects that are often cell context-dependent. Here we tested the impact of enhanced Sirt1 activity in normal and BCR-ABL1-dependent leukemic haematopoiesis in vitro. Using 5-FU enriched murine primary hematopoietic stem and progenitor cells (HSPC) as a model, we report that: 1. Sirt1 over-expression induces 2–3 fold increased, both in frequency and absolute number, of HSPC cells (Lin-Sca1+ckit+) in ‘stem cell-like’ culture condition and enhanced clonogenicity in serial transplantation assay. qRT-PCR analysis showed significantly higher expression of GATA-2 gene in HSPC cells suggesting that Sirt1 promotes GATA-2 mediated HSPC cell proliferation. 2. When HSPC cells were induced to differentiation in the presence of lineage specific growth factor EPO, G-CSF and IL-7, respectively, Sirt1 expression significantly increased the frequency and absolute number of terminal differentiated erythroid (ter119+, 2–3 folds), granulocytic (Gr-1+Cd11b+, 2–3 folds) and B (B220+CD19+, 3–4 folds) cells. Thus, enhanced Sirt1 activity promotes HSPC self-renewal and multiple lineage differentiation. We next tested the effects of Sirt1 activity in Chronic Myeloid Leukaemia (CML). By transducing Sirt1 retrovirus into IL3-dependent BaF3, IL3-independent BCR-ABLp210-expressing BaF3 and primary HSPC cell, we found that Sirt1 over-expression significantly inhibited BCR-ABL1-driven cell proliferation and clonogenicity in cytokine depleted media. In addition, Sirt1 over-expression further reduced the growth rate of BCR-ABLp210 expressing BaF3 cells when treated with TGF-b1, suggesting that Sirt1 might play as a downstream effector of TGF-b signal. Finally, Resveratrol (RSV), a Sirt1 activator, alone and in co-operation with Imatinib, induced cell death and inhibited clonogenicity of CD34+ cells from CML patients with chronic phase. Taken together, our data demonstrate that Sirt1 exhibits contrasting effects in normal and BCR-ABL1-dependent haematopoiesis and suggest that manipulating Sirt1 activity may be a useful strategy to differentially promote normal and inhibit leukemic haematopoiesis in CML. Disclosures: No relevant conflicts of interest to declare.

Role of SIRT1 in Hematologic Malignancies.

SIRT1 Facilitates Hepatocellular Carcinoma Metastasis by Promoting PGC-1α-mediated Mitochondrial Biogenesis.

The Role of SIRT1 in Leukemia

Activation of SIRT1 Deacetylase As a Therapeutic Approach for Myelodysplastic Syndromes By Restoring TET2 Function

SIRT1 Regulates the Phosphorylation and Degradation of P27 by Deacetylating CDK2 to Promote T-cell Acute Lymphoblastic Leukemia Progression.

Multifaceted Modulation of SIRT1 in Cancer and Inflammation.

The role of SIRT1 in tumorigenesis.

Supplementary Figures 1 - 13 from SIRT1 Limits the Function and Fate of Myeloid-Derived Suppressor Cells in Tumors by Orchestrating HIF-1<b>α</b>–Dependent Glycolysis

SIRT1 Inhibition Impairs Non-Homologous End Joining DNA Damage Repair by Increasing Ku70 Acetylation in Chronic Myeloid Leukemia Cells

Recent Advances of SIRT1 and Implications in Chemotherapeutics Resistance in Cancer.

Tet2 Activity is Modulated by Sirt1-Mediated Protein Deacetylation: A Potential Therapeutic Target in Myelodysplastic Syndrome

Diverse Roles of SIRT1 in Cancer Biology and Lipid Metabolism

SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function

The Role of SIRT1 on DNA Damage Response and Epigenetic Alterations in Cancer

Targeting Sirtuins for Cancer Therapy: Epigenetics Modifications and Beyond

Contrasting Effects Of Enhanced Sirt1 Activity In Normal And Bcr-Abl1-Depedent Haematopoiesis

Advances of SIRT4 in Cancer Metabolism and Therapy

AML1-ETO Promotes SIRT1 Expression to Enhance Leukemogenesis of T(8;21) Acute Myeloid Leukemia.

SIRT1: a Potential Tumour Biomarker and Therapeutic Target.

The Clinical Significance of SIRT2 in Malignancies: A Tumor Suppressor or an Oncogene?

The role of SIRT2 in cancer: A novel therapeutic target